Clinical Infection in Practice (Nov 2022)

Oral step-down for Staphylococcus aureus bacteraemia: An opportunity for antimicrobial stewardship?

  • Stephen Platts,
  • Brendan A.I. Payne,
  • D. Ashley Price,
  • Lucia Pareja-Cebrian,
  • Ulrich Schwab

Journal volume & issue
Vol. 16
p. 100202

Abstract

Read online

Objectives: Long courses of intravenous antimicrobial therapy are traditionally recommended for the treatment of methicillin sensitive Staphylococcus aureus bacteraemia (MS-SAB), but are not always completed in clinical practice. Early intravenous to oral antibiotic switch is a key component of antimicrobial stewardship. This study aimed to identify whether intravenous antibiotic duration may be safely reduced in MS-SAB. Methods: We performed a single-centre retrospective study of MS-SAB management. Successful outcome was defined as 90-day recurrence-free survival. Effect of intravenous antibiotic duration on 90-day recurrence risk was examined. Results: 281 adult cases of MS-SAB were evaluated, of which 208 (74 %) had a successful outcome. 176 cases (63 %) received less than 14 days of intravenous antimicrobial therapy. Very short durations of intravenous therapy were associated with increased risk of recurrence (37 %, 2.0 %; p 0.001). Conclusions: Oral antimicrobial switch may allow safe reductions in duration of intravenous therapy in MS-SAB.

Keywords